A technician cultivates lung cells as he preps for research into the infectivity of the SARS-CoV-2 in human lungs at a laboratory at the University of Hong Kong (HKU) in Hong Kong, on Friday, March 20, 2020. Photo: Bloomberg A technician cultivates lung cells as he preps for research into the infectivity of the SARS-CoV-2 in human lungs at a laboratory at the University of Hong Kong (HKU) in Hong Kong, on Friday, March 20, 2020. Photo: Bloomberg
A technician cultivates lung cells as he preps for research into the infectivity of the SARS-CoV-2 in human lungs at a laboratory at the University of Hong Kong (HKU) in Hong Kong, on Friday, March 20, 2020. Photo: Bloomberg
IPO

SciClone and Joinn Laboratories set to joining frenzy for biotech IPOs in Hong Kong as fundraising jumps to highest in two years

  • SciClone Pharmaceuticals, Joinn Laboratories are wrapping up their Hong Kong public offering raising over US$1 billion combined
  • Investors pile into health care IPOs as an earlier deal by cancer screening firm New Horizon Health gets over 4,130 times subscribed

Topic |   IPO
A technician cultivates lung cells as he preps for research into the infectivity of the SARS-CoV-2 in human lungs at a laboratory at the University of Hong Kong (HKU) in Hong Kong, on Friday, March 20, 2020. Photo: Bloomberg A technician cultivates lung cells as he preps for research into the infectivity of the SARS-CoV-2 in human lungs at a laboratory at the University of Hong Kong (HKU) in Hong Kong, on Friday, March 20, 2020. Photo: Bloomberg
A technician cultivates lung cells as he preps for research into the infectivity of the SARS-CoV-2 in human lungs at a laboratory at the University of Hong Kong (HKU) in Hong Kong, on Friday, March 20, 2020. Photo: Bloomberg
READ FULL ARTICLE